Multicenter study of azole-resistant aspergillus fumigatus clinical isolates, Taiwan
Journal
Emerging Infectious Diseases
Journal Volume
26
Journal Issue
4
Pages
806
Date Issued
2020-04-01
Author(s)
Wu, Chi Jung
Liu, Wei Lun
Lai, Chih Cheng
Chao, Chien Ming
Ko, Wen Chien
Wang, Hsuan Chen
Dai, Ching Tzu
Hsieh, Ming I.
Choi, Pui Ching
Yang, Jia Ling
Abstract
© 2020 Centers for Disease Control and Prevention (CDC). All rights reserved. In a multicenter study, we determined a prevalence rate of 4% for azole-resistant Aspergillus fumigatus in Taiwan. Resistance emerged mainly from the environment (TR34/ L98H, TR34/L98H/S297T/F495I, and TR46/Y121F/T289A mutations) but occasionally during azole treatment. A high mortality rate observed for azole-resistant aspergillosis necessitates diagnostic stewardship in healthcare and antifungal stewardship in the environment.
SDGs
Other Subjects
cdr1b protein; difenoconazole; fungal protein; high mobility group B1 protein; pyrrole; sterol 14alpha demethylase; tebuconazole; unclassified drug; voriconazole; antifungal agent; fungal protein; pyrrole derivative; antifungal resistance; antifungal susceptibility; Article; aspergillosis; Aspergillus fumigatus; bacterium isolation; cross resistance; fungal colonization; gene mutation; genotype; human; lung aspergillosis; major clinical study; mortality rate; nonhuman; phylogeny; prevalence; Taiwan; antifungal resistance; Aspergillus fumigatus; clinical trial; epidemiology; genetics; microbial sensitivity test; multicenter study; Antifungal Agents; Aspergillus fumigatus; Azoles; Drug Resistance, Fungal; Fungal Proteins; Microbial Sensitivity Tests; Taiwan
Publisher
CENTERS DISEASE CONTROL & PREVENTION
Type
journal article